The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in diabetic patients with coronary artery disease
Not Applicable
- Conditions
- patients with coronary artery disease and type 2 diabetes
- Registration Number
- JPRN-UMIN000008344
- Lead Sponsor
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
Patients meeting one of the following conditions will be excluded: 1) poor control:HbA1c(NGSP)>8.5, or under treatment of diabetes, or type 1 diabetes 2)severe liver dysfunction 3)severe renal dysfunction (Cre 1.3 mg/dL) 4)severe heart failure) (NYHA/New York Heart Association stage III or severer) 5)Malignancies or other diseases with poor prognosis 6) pregnant, lactating, and possibly pregnant women and those planning to become pregnant 7) past medical history of hypersensitivity to investigational drugs 8) judged as ineligible by clinical investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in coronary plaque character analyzed by coronary angiography, intravascular ultrasound, and optical coherence tomography, and daily glucose profile analyzed by 24-hour continuous glucose monitoring system before and after 6 months treatment with sitagliptin in comparison with metformine
- Secondary Outcome Measures
Name Time Method